GRAIL’s stock closed at $101.53 on Feb. 19, 2026. By the close the next day it was $50.21. That drop of $51.32 a share, or 50.55%, is now the basis for a securities fraud class action against the company and several of its senior executives.
The suit is called Robbins v. GRAIL, Inc., et al., No. 26-cv-05428, and is pending in the U.S. District Court for the Northern District of California. The law firm Bleichmar Fonti & Auld announced it on July 14 and issued a second notice on July 26. These are allegations from a complaint. No court has ruled on them.
What the complaint says
GRAIL, which trades on Nasdaq as GRAL, sells Galleri, a blood test meant to screen for several cancers at once and point to the likely organ where a cancer started. To push for use of the test as a national screening program, the company ran the NHS-Galleri trial with Britain’s National Health Service. Its main goal was “to show a reduction in late-stage (III-IV) cancers in people who received the Galleri test compared with those who did not.”
According to the complaint, GRAIL spoke positively about the test and the trial during the period covered by the suit. It said the trial was “designed with three consecutive years of screening in order to achieve the primary endpoint,” and that “Galleri is working in the real world.” The plaintiffs say that was untrue. In their telling, three years was not long enough to show the main result.
The February results
On Feb. 19, GRAIL released top-line results. The company pointed to some favorable findings, but it also said the trial missed its main target. In its words, the “primary endpoint of statistically significant Stage III-IV reduction was not observed.”
GRAIL blamed the outcome in part on the need for a longer follow-up period to compare the two groups in the study. The stock fell by half the next day.
Claims and deadline
The complaint brings claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of people who bought GRAIL common stock. Investors who want to serve as lead plaintiff have until Aug. 4, 2026 to ask the court to appoint them.
The law firm says it works on a contingency basis, so shareholders would owe no fees or court costs up front, and it would ask the court to approve any fees and expenses. The announcements say the firm has recovered over $900 million in value from Tesla’s board of directors and $420 million from Teva Pharmaceutical.
Sources
- GRAL Court News: GRAIL, Inc. Class Action Lawsuit Alleges Securities Fraud on behalf of Investors with Losses
- GRAIL, Inc. ($GRAL) Investors Notified of August 4 Court Deadline in Securities Fraud Lawsuit Over Trial Results Allegations
